Biocon Limited
Mahindra Manulife Mutual Fund bought 626,000 shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Joint venture between Mahindra Group and Manulife Investment Management of Canada. Manages over Rs 30,000 crore. Focuses on equity and hybrid fund strategies with a quality growth bias inherited from the Manulife global investment framework. Leverages the Mahindra Group's brand and distribution reach for retail investor outreach.